STOK Valuation

Stoke Therapeutics Inc

Add to Watchlist

Advanced Chart

23.500

+0.76(3.342%)1D

Overview
Forecast
Valuation
Earnings

STOK Relative Valuation

STOK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, STOK is overvalued; if below, it's undervalued.

Historical Valuation

Stoke Therapeutics Inc (STOK) is now in the Overvalued zone, suggesting that its current forward PS ratio of 71.05 is considered Overvalued compared with the five-year average of -8.49. The fair price of Stoke Therapeutics Inc (STOK) is between 3.98 to 17.18 according to relative valuation methord. Compared to the current price of 23.14 USD , Stoke Therapeutics Inc is Overvalued By 34.67%.

Relative Value

Fair Zone

3.98-17.18

Current Price：23.14

34.67%

Overvalued

-8.87

Trailing

Forward

-8.97

EV/EBITDA

Stoke Therapeutics Inc. (STOK) has a current EV/EBITDA of -8.97. The 5-year average EV/EBITDA is -5.77. The thresholds are as follows: Strongly Undervalued below -19.53, Undervalued between -19.53 and -12.65, Fairly Valued between 1.11 and -12.65, Overvalued between 1.11 and 7.99, and Strongly Overvalued above 7.99. The current Forward EV/EBITDA of -8.97 falls within the Historic Trend Line -Fairly Valued range.

-5.54

EV/EBIT

Stoke Therapeutics Inc. (STOK) has a current EV/EBIT of -5.54. The 5-year average EV/EBIT is -5.40. The thresholds are as follows: Strongly Undervalued below -18.44, Undervalued between -18.44 and -11.92, Fairly Valued between 1.12 and -11.92, Overvalued between 1.12 and 7.64, and Strongly Overvalued above 7.64. The current Forward EV/EBIT of -5.54 falls within the Historic Trend Line -Fairly Valued range.

71.05

Stoke Therapeutics Inc. (STOK) has a current PS of 71.05. The 5-year average PS is 34.03. The thresholds are as follows: Strongly Undervalued below -16.61, Undervalued between -16.61 and 8.71, Fairly Valued between 59.35 and 8.71, Overvalued between 59.35 and 84.67, and Strongly Overvalued above 84.67. The current Forward PS of 71.05 falls within the Overvalued range.

-8.50

P/OCF

Stoke Therapeutics Inc. (STOK) has a current P/OCF of -8.50. The 5-year average P/OCF is -12.13. The thresholds are as follows: Strongly Undervalued below -36.53, Undervalued between -36.53 and -24.33, Fairly Valued between 0.07 and -24.33, Overvalued between 0.07 and 12.28, and Strongly Overvalued above 12.28. The current Forward P/OCF of -8.50 falls within the Historic Trend Line -Fairly Valued range.

-15.96

P/FCF

Stoke Therapeutics Inc. (STOK) has a current P/FCF of -15.96. The 5-year average P/FCF is -47.13. The thresholds are as follows: Strongly Undervalued below -380.04, Undervalued between -380.04 and -213.58, Fairly Valued between 119.33 and -213.58, Overvalued between 119.33 and 285.78, and Strongly Overvalued above 285.78. The current Forward P/FCF of -15.96 falls within the Historic Trend Line -Fairly Valued range.

Stoke Therapeutics Inc (STOK) has a current Price-to-Book (P/B) ratio of 3.72. Compared to its 3-year average P/B ratio of 2.27 , the current P/B ratio is approximately 63.56% higher. Relative to its 5-year average P/B ratio of 3.21, the current P/B ratio is about 15.83% higher. Stoke Therapeutics Inc (STOK) has a Forward Free Cash Flow (FCF) yield of approximately 4.82%. Compared to its 3-year average FCF yield of -16.27%, the current FCF yield is approximately -129.62% lower. Relative to its 5-year average FCF yield of -11.61% , the current FCF yield is about -141.49% lower.

3.72

P/B

Median3y

2.27

Median5y

3.21

4.82

FCF Yield

Median3y

-16.27

Median5y

-11.61

Competitors Valuation Multiple

The average P/S ratio for STOK's competitors is 23.01, providing a benchmark for relative valuation. Stoke Therapeutics Inc Corp (STOK) exhibits a P/S ratio of 71.05, which is 208.79% above the industry average. Given its robust revenue growth of 186.01%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

STOK.O

Stoke Therapeutics Inc

Abcellera Biologics Inc

Syndax Pharmaceuticals Inc

Arcus Biosciences Inc

Intellia Therapeutics Inc

25.77

104.76%

1.33B

Performance Decomposition

Market capitalization of STOK increased by 85.03% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 4.83M to 13.82M.

The secondary factor is the P/E Change, contributed -32.93%to the performance.

Overall, the performance of STOK in the past 1 year is driven by Revenue Growth. Which is more sustainable.

186.01%

4.83M → 13.82M

Revenue Growth

-68.05%

-531.88 → -169.96

Margin Expansion

-32.93%

37.34 → 25.04

P/E Change

85.03%